Effimune has signed Global License Agreement with Janssen Biotech, member of Johnson & Johnson Group

 

Nantes (France) – October 3, 2013 –

Effimune, a biotech company dedicated to the discovery and development of drugs which regulate the immune system in autoimmune disease and transplantation, announced today a global option and license agreement with Janssen Biotech, Inc. (Janssen). The collaboration between Effimune, the London Innovation Centre of Johnson & Johnson Innovation and the Janssen Immunology Therapeutic Area is focused on the development and commercialization of FR104, a monoclonal antibody fragment in preclinical development for the treatment of immune- mediated disorders.

Read the Press Release

Lire le communiqué de presse

Cutting-edge Products

fr-104

The 1st product-candidate, called FR104, resulting from company’s research platform is currently in clinical trials in the frame of a lisencing agreement with Janssen Biotech Inc.. The second product-candidate, Effi7, takes part of a French consortium financed by Bpifrance.

Read more

World-class research talent

research-talents

Surrounding by a dynamic and fruitful hub, Effimune highly qualified team uses its wealth of expertise to keep the immune system in check.

Read more

Breakthrough Technology

breakthrough-technology

Effimune develops therapeutic recombinant monoclonal antibodies (mAbs) that are predicted to be the strongest performing molecule type across the branded prescription pharmaceutical.

Read more

Expertise in immunomodulation

expertise

Effimune S.A is a biotechnology company conducting research and development of innovative drug candidates for transplantation and immune-mediated diseases.
The company specializes in the development of first-in-class biological drug candidates targeting cells of the immune system to restore the balance between effector and regulatory mechanisms. Three product candidates are currently in development, one of them in collaboration with our partners Janssen Biotech.

Read more